Multiple sclerosis (Simple English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Multiple sclerosis" in Simple English language version.

Last modified: 15:40:44, 26 July 2026 (UTC)

Ref.Un. Ref.Website

Global rank Simple English rank

5630nih.gov

5^th place

4923doi.org

2^nd place

4015semanticscholar.org

15^th place

11^th place

329archive.org

6^th place

3^rd place

101adsabs.harvard.edu

14^th place

17^th place

11hdl.handle.net

66^th place

172^nd place

11fda.gov

470^th place

788^th place

11web.archive.org

1^st place

11novartis.com

low place

adsabs.harvard.edu (Global: 14^th place; Simple English: 17^th place)

ui.adsabs.harvard.edu

Compston, Alastair; Coles, Alasdair (Oct 25, 2008). "Multiple sclerosis". Lancet. 372 (9648): 1502–17. Bibcode:2008Lanc..372.1502C. doi:10.1016/S0140-6736(08)61620-7. PMID 18970977. S2CID 195686659.

archive.org (Global: 6^th place; Simple English: 3^rd place)

Compston, Alastair; Coles, Alasdair (Oct 25, 2008). "Multiple sclerosis". Lancet. 372 (9648): 1502–17. Bibcode:2008Lanc..372.1502C. doi:10.1016/S0140-6736(08)61620-7. PMID 18970977. S2CID 195686659.
Compston, Alastair; Coles, Alasdair (Apr 6, 2002). "Multiple sclerosis". Lancet. 359 (9313): 1221–31. doi:10.1016/S0140-6736(02)08220-X. PMID 11955556. S2CID 14207583.
Ascherio, Alberto; Munger, Kassandra L. (Jun 2007). "Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors". Annals of Neurology. 61 (6): 504–13. doi:10.1002/ana.21141. PMID 17492755. S2CID 36999504.
Ascherio, Alberto; Munger, Kassandra L. (Apr 2007). "Environmental risk factors for multiple sclerosis. Part I: the role of infection". Annals of Neurology. 61 (4): 288–99. doi:10.1002/ana.21117. PMID 17444504. S2CID 7682774.
Kurtzke, JF (Oct 1993). "Epidemiologic evidence for multiple sclerosis as an infection". Clinical Microbiology Reviews. 6 (4): 382–427. doi:10.1128/CMR.6.4.382. PMC 358295. PMID 8269393.
Lublin, F. D.; Reingold, S. C. (Apr 1996). "Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis". Neurology. 46 (4): 907–11. doi:10.1212/wnl.46.4.907. PMID 8780061. S2CID 40213123.
Alonso, A.; Hernan, M. A. (Jul 8, 2008). "Temporal trends in the incidence of multiple sclerosis: a systematic review". Neurology. 71 (2): 129–35. doi:10.1212/01.wnl.0000316802.35974.34. PMC 4109189. PMID 18606967.
McDonald, W. Ian; Compston, Alistair; Edan, Gilles; Goodkin, Donald; Hartung, Hans-Peter; Lublin, Fred D.; McFarland, Henry F.; Paty, Donald W.; Polman, Chris H.; Reingold, Stephen C.; Sandberg-Wollheim, Magnhild; Sibley, William; Thompson, Alan; Van Den Noort, Stanley; Weinshenker, Brian Y.; Wolinsky, Jerry S. (Jul 2001). "Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis". Annals of Neurology. 50 (1): 121–7. doi:10.1002/ana.1032. PMID 11456302. S2CID 13870943.
Gronseth, G. S.; Ashman, E. J. (May 9, 2000). "Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology". Neurology. 54 (9): 1720–5. doi:10.1212/wnl.54.9.1720. PMID 10802774. S2CID 9635808.

doi.org (Global: 2^nd place; Simple English: 2^nd place)

Compston, Alastair; Coles, Alasdair (Oct 25, 2008). "Multiple sclerosis". Lancet. 372 (9648): 1502–17. Bibcode:2008Lanc..372.1502C. doi:10.1016/S0140-6736(08)61620-7. PMID 18970977. S2CID 195686659.
Compston, Alastair; Coles, Alasdair (Apr 6, 2002). "Multiple sclerosis". Lancet. 359 (9313): 1221–31. doi:10.1016/S0140-6736(02)08220-X. PMID 11955556. S2CID 14207583.
Dyment, David A.; Ebers, George C.; Dessa Sadovnick, A. (Feb 2004). "Genetics of multiple sclerosis". Lancet Neurology. 3 (2): 104–10. doi:10.1016/s1474-4422(03)00663-x. PMID 14747002. S2CID 16707321.
Marrie, RA (Dec 2004). "Environmental risk factors in multiple sclerosis aetiology". Lancet Neurology. 3 (12): 709–18. doi:10.1016/S1474-4422(04)00933-0. PMID 15556803. S2CID 175786.
Ascherio, Alberto; Munger, Kassandra L. (Jun 2007). "Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors". Annals of Neurology. 61 (6): 504–13. doi:10.1002/ana.21141. PMID 17492755. S2CID 36999504.
Ascherio, Alberto; Munger, Kassandra L.; Simon, K Claire (Jun 2010). "Vitamin D and multiple sclerosis". Lancet Neurology. 9 (6): 599–612. doi:10.1016/S1474-4422(10)70086-7. PMID 20494325. S2CID 12802790.
Ascherio, Alberto; Munger, Kassandra L. (Apr 2007). "Environmental risk factors for multiple sclerosis. Part I: the role of infection". Annals of Neurology. 61 (4): 288–99. doi:10.1002/ana.21117. PMID 17444504. S2CID 7682774.
Kurtzke, JF (Oct 1993). "Epidemiologic evidence for multiple sclerosis as an infection". Clinical Microbiology Reviews. 6 (4): 382–427. doi:10.1128/CMR.6.4.382. PMC 358295. PMID 8269393.
Gilden, DH (Mar 2005). "Infectious causes of multiple sclerosis". Lancet Neurology. 4 (3): 195–202. doi:10.1016/S1474-4422(05)01017-3. PMC 7129502. PMID 15721830.
Lublin, F. D.; Reingold, S. C. (Apr 1996). "Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis". Neurology. 46 (4): 907–11. doi:10.1212/wnl.46.4.907. PMID 8780061. S2CID 40213123.
Bramow, Stephan; Frischer, Josa M.; Lassmann, Hans; Koch-Henriksen, Nils; Lucchinetti, Claudia F.; Sørensen, Per S.; Laursen, Henning (20 September 2010). "Demyelination versus remyelination in progressive multiple sclerosis". Brain. 133 (10): 2983–2998. doi:10.1093/brain/awq250. PMID 20855416.
Ho, Peggy P.; Kanter, Jennifer L.; Johnson, Amanda M.; Srinagesh, Hrishikesh K.; Chang, Eun-Ju; Purdy, Timothy M.; Van Haren, Keith; Wikoff, William R.; Kind, Tobias; Khademi, Mohsen; Matloff, Laura Y.; Narayana, Sirisha; Hur, Eun Mi; Lindstrom, Tamsin M.; He, Zhigang; Fiehn, Oliver; Olsson, Tomas; Han, Xianlin; Han, May H.; Steinman, Lawrence; Robinson, William H. (2012). "Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation". Science Translational Medicine. 4 (137): 137–73. doi:10.1126/scitranslmed.3003831. PMC 3953135. PMID 22674551.
Pittock, S. J.; Lucchinetti, C. F. (Mar 2007). "The pathology of MS: new insights and potential clinical applications". The Neurologist. 13 (2): 45–56. doi:10.1097/01.nrl.0000253065.31662.37. PMID 17351524. S2CID 2993523.
Alonso, A.; Hernan, M. A. (Jul 8, 2008). "Temporal trends in the incidence of multiple sclerosis: a systematic review". Neurology. 71 (2): 129–35. doi:10.1212/01.wnl.0000316802.35974.34. PMC 4109189. PMID 18606967.
McDonald, W. Ian; Compston, Alistair; Edan, Gilles; Goodkin, Donald; Hartung, Hans-Peter; Lublin, Fred D.; McFarland, Henry F.; Paty, Donald W.; Polman, Chris H.; Reingold, Stephen C.; Sandberg-Wollheim, Magnhild; Sibley, William; Thompson, Alan; Van Den Noort, Stanley; Weinshenker, Brian Y.; Wolinsky, Jerry S. (Jul 2001). "Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis". Annals of Neurology. 50 (1): 121–7. doi:10.1002/ana.1032. PMID 11456302. S2CID 13870943.
Link, Hans; Huang, Yu-Min (Nov 2006). "Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness". Journal of Neuroimmunology. 180 (1–2): 17–28. doi:10.1016/j.jneuroim.2006.07.006. PMID 16945427. S2CID 22724352.
Rashid, Waqar; Miller, David (Feb 2008). "Recent advances in neuroimaging of multiple sclerosis". Seminars in Neurology. 28 (1): 46–55. doi:10.1055/s-2007-1019127. PMID 18256986. S2CID 260317568.
Gronseth, G. S.; Ashman, E. J. (May 9, 2000). "Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology". Neurology. 54 (9): 1720–5. doi:10.1212/wnl.54.9.1720. PMID 10802774. S2CID 9635808.
Skrzipek, Sabine; Vogelgesang, Antje; Bröker, Barbara M.; Dressel, Alexander (24 October 2011). "Differential effects of interferon-ss1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients". Multiple Sclerosis Journal. 18 (5): 674–678. doi:10.1177/1352458511427317. PMID 22025329. S2CID 206698737.
Burton, Jodie M.; O'Connor, Paul W.; Hohol, Marika; Beyene, Joseph (2012-12-12). "Oral versus intravenous steroids for treatment of relapses in multiple sclerosis". Cochrane Database of Systematic Reviews (Online). 2012 (12) CD006921. doi:10.1002/14651858.CD006921.pub3. PMC 12145957. PMID 23235634.
Marriott, J. J.; Miyasaki, J. M.; Gronseth, G.; O'Connor, P. W.; Therapeutics Technology Assessment Subcommittee of the American Academy of Neurology (2010-05-04). "Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 74 (18): 1463–70. doi:10.1212/WNL.0b013e3181dc1ae0. PMC 2871006. PMID 20439849.
Kappos, Ludwig; Bates, David; Edan, Gilles; Eraksoy, Mefkûre; Garcia-Merino, Antonio; Grigoriadis, Nikolaos; Hartung, Hans-Peter; Havrdová, Eva; Hillert, Jan; Hohlfeld, Reinhard; Kremenchutzky, Marcelo; Lyon-Caen, Olivier; Miller, Ariel; Pozzilli, Carlo; Ravnborg, Mads; Saida, Takahiko; Sindic, Christian; Vass, Karl; Clifford, David B.; Hauser, Stephen; Major, Eugene O.; O'Connor, Paul W.; Weiner, Howard L.; Clanet, Michel; Gold, Ralf; Hirsch, Hans H.; Radü, Ernst-Wilhelm; Sørensen, Per Soelberg; King, John (Aug 2011). "Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring". Lancet Neurology. 10 (8): 745–58. doi:10.1016/S1474-4422(11)70149-1. hdl:2078.1/124907. PMID 21777829. S2CID 15639613.
Olsen, SA (2009). "A review of complementary and alternative medicine (CAM) by people with multiple sclerosis". Occupational Therapy International. 16 (1): 57–70. doi:10.1002/oti.266. PMID 19222053.

fda.gov (Global: 470^th place; Simple English: 788^th place)

"FDA approves new multiple sclerosis treatment (Press release)". US FDA. 12 September 2012. Retrieved 31 March 2013.

hdl.handle.net (Global: 66^th place; Simple English: 172^nd place)

Kappos, Ludwig; Bates, David; Edan, Gilles; Eraksoy, Mefkûre; Garcia-Merino, Antonio; Grigoriadis, Nikolaos; Hartung, Hans-Peter; Havrdová, Eva; Hillert, Jan; Hohlfeld, Reinhard; Kremenchutzky, Marcelo; Lyon-Caen, Olivier; Miller, Ariel; Pozzilli, Carlo; Ravnborg, Mads; Saida, Takahiko; Sindic, Christian; Vass, Karl; Clifford, David B.; Hauser, Stephen; Major, Eugene O.; O'Connor, Paul W.; Weiner, Howard L.; Clanet, Michel; Gold, Ralf; Hirsch, Hans H.; Radü, Ernst-Wilhelm; Sørensen, Per Soelberg; King, John (Aug 2011). "Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring". Lancet Neurology. 10 (8): 745–58. doi:10.1016/S1474-4422(11)70149-1. hdl:2078.1/124907. PMID 21777829. S2CID 15639613.

nih.gov (Global: 5^th place; Simple English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Compston, Alastair; Coles, Alasdair (Oct 25, 2008). "Multiple sclerosis". Lancet. 372 (9648): 1502–17. Bibcode:2008Lanc..372.1502C. doi:10.1016/S0140-6736(08)61620-7. PMID 18970977. S2CID 195686659.
Compston, Alastair; Coles, Alasdair (Apr 6, 2002). "Multiple sclerosis". Lancet. 359 (9313): 1221–31. doi:10.1016/S0140-6736(02)08220-X. PMID 11955556. S2CID 14207583.
Dyment, David A.; Ebers, George C.; Dessa Sadovnick, A. (Feb 2004). "Genetics of multiple sclerosis". Lancet Neurology. 3 (2): 104–10. doi:10.1016/s1474-4422(03)00663-x. PMID 14747002. S2CID 16707321.
Marrie, RA (Dec 2004). "Environmental risk factors in multiple sclerosis aetiology". Lancet Neurology. 3 (12): 709–18. doi:10.1016/S1474-4422(04)00933-0. PMID 15556803. S2CID 175786.
Ascherio, Alberto; Munger, Kassandra L. (Jun 2007). "Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors". Annals of Neurology. 61 (6): 504–13. doi:10.1002/ana.21141. PMID 17492755. S2CID 36999504.
Ascherio, Alberto; Munger, Kassandra L.; Simon, K Claire (Jun 2010). "Vitamin D and multiple sclerosis". Lancet Neurology. 9 (6): 599–612. doi:10.1016/S1474-4422(10)70086-7. PMID 20494325. S2CID 12802790.
Ascherio, Alberto; Munger, Kassandra L. (Apr 2007). "Environmental risk factors for multiple sclerosis. Part I: the role of infection". Annals of Neurology. 61 (4): 288–99. doi:10.1002/ana.21117. PMID 17444504. S2CID 7682774.
Kurtzke, JF (Oct 1993). "Epidemiologic evidence for multiple sclerosis as an infection". Clinical Microbiology Reviews. 6 (4): 382–427. doi:10.1128/CMR.6.4.382. PMC 358295. PMID 8269393.
Gilden, DH (Mar 2005). "Infectious causes of multiple sclerosis". Lancet Neurology. 4 (3): 195–202. doi:10.1016/S1474-4422(05)01017-3. PMC 7129502. PMID 15721830.
Lublin, F. D.; Reingold, S. C. (Apr 1996). "Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis". Neurology. 46 (4): 907–11. doi:10.1212/wnl.46.4.907. PMID 8780061. S2CID 40213123.
Bramow, Stephan; Frischer, Josa M.; Lassmann, Hans; Koch-Henriksen, Nils; Lucchinetti, Claudia F.; Sørensen, Per S.; Laursen, Henning (20 September 2010). "Demyelination versus remyelination in progressive multiple sclerosis". Brain. 133 (10): 2983–2998. doi:10.1093/brain/awq250. PMID 20855416.
Ho, Peggy P.; Kanter, Jennifer L.; Johnson, Amanda M.; Srinagesh, Hrishikesh K.; Chang, Eun-Ju; Purdy, Timothy M.; Van Haren, Keith; Wikoff, William R.; Kind, Tobias; Khademi, Mohsen; Matloff, Laura Y.; Narayana, Sirisha; Hur, Eun Mi; Lindstrom, Tamsin M.; He, Zhigang; Fiehn, Oliver; Olsson, Tomas; Han, Xianlin; Han, May H.; Steinman, Lawrence; Robinson, William H. (2012). "Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation". Science Translational Medicine. 4 (137): 137–73. doi:10.1126/scitranslmed.3003831. PMC 3953135. PMID 22674551.
Pittock, S. J.; Lucchinetti, C. F. (Mar 2007). "The pathology of MS: new insights and potential clinical applications". The Neurologist. 13 (2): 45–56. doi:10.1097/01.nrl.0000253065.31662.37. PMID 17351524. S2CID 2993523.
Alonso, A.; Hernan, M. A. (Jul 8, 2008). "Temporal trends in the incidence of multiple sclerosis: a systematic review". Neurology. 71 (2): 129–35. doi:10.1212/01.wnl.0000316802.35974.34. PMC 4109189. PMID 18606967.
McDonald, W. Ian; Compston, Alistair; Edan, Gilles; Goodkin, Donald; Hartung, Hans-Peter; Lublin, Fred D.; McFarland, Henry F.; Paty, Donald W.; Polman, Chris H.; Reingold, Stephen C.; Sandberg-Wollheim, Magnhild; Sibley, William; Thompson, Alan; Van Den Noort, Stanley; Weinshenker, Brian Y.; Wolinsky, Jerry S. (Jul 2001). "Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis". Annals of Neurology. 50 (1): 121–7. doi:10.1002/ana.1032. PMID 11456302. S2CID 13870943.
Link, Hans; Huang, Yu-Min (Nov 2006). "Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness". Journal of Neuroimmunology. 180 (1–2): 17–28. doi:10.1016/j.jneuroim.2006.07.006. PMID 16945427. S2CID 22724352.
Rashid, Waqar; Miller, David (Feb 2008). "Recent advances in neuroimaging of multiple sclerosis". Seminars in Neurology. 28 (1): 46–55. doi:10.1055/s-2007-1019127. PMID 18256986. S2CID 260317568.
Gronseth, G. S.; Ashman, E. J. (May 9, 2000). "Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology". Neurology. 54 (9): 1720–5. doi:10.1212/wnl.54.9.1720. PMID 10802774. S2CID 9635808.
Skrzipek, Sabine; Vogelgesang, Antje; Bröker, Barbara M.; Dressel, Alexander (24 October 2011). "Differential effects of interferon-ss1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients". Multiple Sclerosis Journal. 18 (5): 674–678. doi:10.1177/1352458511427317. PMID 22025329. S2CID 206698737.
Burton, Jodie M.; O'Connor, Paul W.; Hohol, Marika; Beyene, Joseph (2012-12-12). "Oral versus intravenous steroids for treatment of relapses in multiple sclerosis". Cochrane Database of Systematic Reviews (Online). 2012 (12) CD006921. doi:10.1002/14651858.CD006921.pub3. PMC 12145957. PMID 23235634.
Marriott, J. J.; Miyasaki, J. M.; Gronseth, G.; O'Connor, P. W.; Therapeutics Technology Assessment Subcommittee of the American Academy of Neurology (2010-05-04). "Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 74 (18): 1463–70. doi:10.1212/WNL.0b013e3181dc1ae0. PMC 2871006. PMID 20439849.
Kappos, Ludwig; Bates, David; Edan, Gilles; Eraksoy, Mefkûre; Garcia-Merino, Antonio; Grigoriadis, Nikolaos; Hartung, Hans-Peter; Havrdová, Eva; Hillert, Jan; Hohlfeld, Reinhard; Kremenchutzky, Marcelo; Lyon-Caen, Olivier; Miller, Ariel; Pozzilli, Carlo; Ravnborg, Mads; Saida, Takahiko; Sindic, Christian; Vass, Karl; Clifford, David B.; Hauser, Stephen; Major, Eugene O.; O'Connor, Paul W.; Weiner, Howard L.; Clanet, Michel; Gold, Ralf; Hirsch, Hans H.; Radü, Ernst-Wilhelm; Sørensen, Per Soelberg; King, John (Aug 2011). "Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring". Lancet Neurology. 10 (8): 745–58. doi:10.1016/S1474-4422(11)70149-1. hdl:2078.1/124907. PMID 21777829. S2CID 15639613.
Olsen, SA (2009). "A review of complementary and alternative medicine (CAM) by people with multiple sclerosis". Occupational Therapy International. 16 (1): 57–70. doi:10.1002/oti.266. PMID 19222053.

ncbi.nlm.nih.gov

Kurtzke, JF (Oct 1993). "Epidemiologic evidence for multiple sclerosis as an infection". Clinical Microbiology Reviews. 6 (4): 382–427. doi:10.1128/CMR.6.4.382. PMC 358295. PMID 8269393.
Gilden, DH (Mar 2005). "Infectious causes of multiple sclerosis". Lancet Neurology. 4 (3): 195–202. doi:10.1016/S1474-4422(05)01017-3. PMC 7129502. PMID 15721830.
Ho, Peggy P.; Kanter, Jennifer L.; Johnson, Amanda M.; Srinagesh, Hrishikesh K.; Chang, Eun-Ju; Purdy, Timothy M.; Van Haren, Keith; Wikoff, William R.; Kind, Tobias; Khademi, Mohsen; Matloff, Laura Y.; Narayana, Sirisha; Hur, Eun Mi; Lindstrom, Tamsin M.; He, Zhigang; Fiehn, Oliver; Olsson, Tomas; Han, Xianlin; Han, May H.; Steinman, Lawrence; Robinson, William H. (2012). "Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation". Science Translational Medicine. 4 (137): 137–73. doi:10.1126/scitranslmed.3003831. PMC 3953135. PMID 22674551.
Alonso, A.; Hernan, M. A. (Jul 8, 2008). "Temporal trends in the incidence of multiple sclerosis: a systematic review". Neurology. 71 (2): 129–35. doi:10.1212/01.wnl.0000316802.35974.34. PMC 4109189. PMID 18606967.
Burton, Jodie M.; O'Connor, Paul W.; Hohol, Marika; Beyene, Joseph (2012-12-12). "Oral versus intravenous steroids for treatment of relapses in multiple sclerosis". Cochrane Database of Systematic Reviews (Online). 2012 (12) CD006921. doi:10.1002/14651858.CD006921.pub3. PMC 12145957. PMID 23235634.
Marriott, J. J.; Miyasaki, J. M.; Gronseth, G.; O'Connor, P. W.; Therapeutics Technology Assessment Subcommittee of the American Academy of Neurology (2010-05-04). "Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 74 (18): 1463–70. doi:10.1212/WNL.0b013e3181dc1ae0. PMC 2871006. PMID 20439849.

nlm.nih.gov

"Natalizumab Injection". US National Library of Medicine (Medline). 2012-05-15. Retrieved 31 March 2013.

novartis.com (Global: low place; Simple English: low place)

pharma.us.novartis.com

"Gylenya medication guide" (PDF). Novartis Pharmaceuticals Corporation. May 2012. p. 2. Archived from the original (PDF) on 28 February 2013. Retrieved 31 March 2013.

semanticscholar.org (Global: 15^th place; Simple English: 11^th place)

api.semanticscholar.org

Compston, Alastair; Coles, Alasdair (Oct 25, 2008). "Multiple sclerosis". Lancet. 372 (9648): 1502–17. Bibcode:2008Lanc..372.1502C. doi:10.1016/S0140-6736(08)61620-7. PMID 18970977. S2CID 195686659.
Compston, Alastair; Coles, Alasdair (Apr 6, 2002). "Multiple sclerosis". Lancet. 359 (9313): 1221–31. doi:10.1016/S0140-6736(02)08220-X. PMID 11955556. S2CID 14207583.
Dyment, David A.; Ebers, George C.; Dessa Sadovnick, A. (Feb 2004). "Genetics of multiple sclerosis". Lancet Neurology. 3 (2): 104–10. doi:10.1016/s1474-4422(03)00663-x. PMID 14747002. S2CID 16707321.
Marrie, RA (Dec 2004). "Environmental risk factors in multiple sclerosis aetiology". Lancet Neurology. 3 (12): 709–18. doi:10.1016/S1474-4422(04)00933-0. PMID 15556803. S2CID 175786.
Ascherio, Alberto; Munger, Kassandra L. (Jun 2007). "Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors". Annals of Neurology. 61 (6): 504–13. doi:10.1002/ana.21141. PMID 17492755. S2CID 36999504.
Ascherio, Alberto; Munger, Kassandra L.; Simon, K Claire (Jun 2010). "Vitamin D and multiple sclerosis". Lancet Neurology. 9 (6): 599–612. doi:10.1016/S1474-4422(10)70086-7. PMID 20494325. S2CID 12802790.
Ascherio, Alberto; Munger, Kassandra L. (Apr 2007). "Environmental risk factors for multiple sclerosis. Part I: the role of infection". Annals of Neurology. 61 (4): 288–99. doi:10.1002/ana.21117. PMID 17444504. S2CID 7682774.
Lublin, F. D.; Reingold, S. C. (Apr 1996). "Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis". Neurology. 46 (4): 907–11. doi:10.1212/wnl.46.4.907. PMID 8780061. S2CID 40213123.
Pittock, S. J.; Lucchinetti, C. F. (Mar 2007). "The pathology of MS: new insights and potential clinical applications". The Neurologist. 13 (2): 45–56. doi:10.1097/01.nrl.0000253065.31662.37. PMID 17351524. S2CID 2993523.
McDonald, W. Ian; Compston, Alistair; Edan, Gilles; Goodkin, Donald; Hartung, Hans-Peter; Lublin, Fred D.; McFarland, Henry F.; Paty, Donald W.; Polman, Chris H.; Reingold, Stephen C.; Sandberg-Wollheim, Magnhild; Sibley, William; Thompson, Alan; Van Den Noort, Stanley; Weinshenker, Brian Y.; Wolinsky, Jerry S. (Jul 2001). "Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis". Annals of Neurology. 50 (1): 121–7. doi:10.1002/ana.1032. PMID 11456302. S2CID 13870943.
Link, Hans; Huang, Yu-Min (Nov 2006). "Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness". Journal of Neuroimmunology. 180 (1–2): 17–28. doi:10.1016/j.jneuroim.2006.07.006. PMID 16945427. S2CID 22724352.
Rashid, Waqar; Miller, David (Feb 2008). "Recent advances in neuroimaging of multiple sclerosis". Seminars in Neurology. 28 (1): 46–55. doi:10.1055/s-2007-1019127. PMID 18256986. S2CID 260317568.
Gronseth, G. S.; Ashman, E. J. (May 9, 2000). "Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology". Neurology. 54 (9): 1720–5. doi:10.1212/wnl.54.9.1720. PMID 10802774. S2CID 9635808.
Skrzipek, Sabine; Vogelgesang, Antje; Bröker, Barbara M.; Dressel, Alexander (24 October 2011). "Differential effects of interferon-ss1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients". Multiple Sclerosis Journal. 18 (5): 674–678. doi:10.1177/1352458511427317. PMID 22025329. S2CID 206698737.
Kappos, Ludwig; Bates, David; Edan, Gilles; Eraksoy, Mefkûre; Garcia-Merino, Antonio; Grigoriadis, Nikolaos; Hartung, Hans-Peter; Havrdová, Eva; Hillert, Jan; Hohlfeld, Reinhard; Kremenchutzky, Marcelo; Lyon-Caen, Olivier; Miller, Ariel; Pozzilli, Carlo; Ravnborg, Mads; Saida, Takahiko; Sindic, Christian; Vass, Karl; Clifford, David B.; Hauser, Stephen; Major, Eugene O.; O'Connor, Paul W.; Weiner, Howard L.; Clanet, Michel; Gold, Ralf; Hirsch, Hans H.; Radü, Ernst-Wilhelm; Sørensen, Per Soelberg; King, John (Aug 2011). "Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring". Lancet Neurology. 10 (8): 745–58. doi:10.1016/S1474-4422(11)70149-1. hdl:2078.1/124907. PMID 21777829. S2CID 15639613.

web.archive.org (Global: 1^st place; Simple English: 1^st place)

"Gylenya medication guide" (PDF). Novartis Pharmaceuticals Corporation. May 2012. p. 2. Archived from the original (PDF) on 28 February 2013. Retrieved 31 March 2013.

Multiple sclerosis (Simple English Wikipedia)

adsabs.harvard.edu (Global: 14th place; Simple English: 17th place)

ui.adsabs.harvard.edu

archive.org (Global: 6th place; Simple English: 3rd place)

doi.org (Global: 2nd place; Simple English: 2nd place)

fda.gov (Global: 470th place; Simple English: 788th place)

hdl.handle.net (Global: 66th place; Simple English: 172nd place)

nih.gov (Global: 5th place; Simple English: 5th place)